AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics, a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer.

The expanded indications increase physician access to the NanoKnife System’s irreversible electroporation (IRE) technology across key oncologic applications, supporting the treatment of patients with tumors that may be difficult to resect or located near critical structures.

The NanoKnife System utilizes irreversible electroporation (IRE), a non-thermal ablation technology designed to destroy tumor cells while preserving critical surrounding anatomy such as blood vessels, bile ducts, and nerves. This differentiated mechanism of action makes it particularly suited for tumors located in complex anatomical regions, such as the pancreas and liver.

“NanoKnife prostate continues to gain clinical traction, and we remain committed to advancing that indication globally,” said Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International. “The expansion of additional organ indications in Europe underscores the broader potential of IRE technology and strengthens NanoKnife as a scalable platform for complex tumor ablation. Our goal is to ensure physicians have access to differentiated tools that expand treatment options for patients across multiple disease states.”

A growing body of clinical evidence supports the use of the NanoKnife System’s IRE technology across multiple solid tumor indications. Prospective and multicenter studies have demonstrated procedural feasibility and encouraging clinical outcomes in metastatic colorectal cancer,¹ liver and pancreatic cancer,^2,3 hepatocellular carcinoma,⁴ and renal tumors. Comparative and real-world analyses continue to reinforce the safety profile and expanding clinical utility of IRE in anatomically challenging disease states.^5,6,7

Collectively, this expanding evidence base has contributed to increasing physician adoption of IRE across Europe and other global markets.

Europe accounts for approximately 28% of global IRE procedures. Annual IRE procedures are estimated to have surpassed 45,000 globally and continue to grow, supported by rising cancer incidence, expanding physician adoption, technological advancements in image guidance, and strong demand for minimally invasive treatment options.⁸

The expanded indications position the NanoKnife System to participate more broadly across this growing European market and reinforce its role as a multi-organ tumor ablation platform.

To further support clinical adoption and long-term evidence development, AngioDynamics will initiate the LIVER-IRE Global Registry in collaboration with Professor Ajith Siriwardena, MD FRCS, at the University of Manchester in the United Kingdom. The registry is designed to prospectively evaluate outcomes in patients undergoing IRE treatment for liver tumors and contribute to the growing body of real-world clinical data supporting multi-organ applications of the NanoKnife System technology.

“Irreversible electroporation offers an important treatment consideration for patients with liver tumors located near critical structures,” said Professor Siriwardena. “The LIVER-IRE Registry will help further characterize outcomes in real-world practice.”

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Albert Baines today!